Brookfield Asset Management Inc. Seagen Inc. Transaction History

Brookfield Asset Management Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Sep 25, 2023	BUY	$187.64 - $206.25 $7.51 Million - $8.25 Million	40,000 Added 800.0%	45,000 $8.66 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $7.51 Million - $8.25 Million	40,000 Added 800.0%	45,000 $8.66 Million
Q1 2023 Sep 25, 2023	SELL	$127.59 - $203.08 $5.1 Million - $8.12 Million	-40,000 Reduced 88.89%	5,000 $1.01 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $637,950 - $1.02 Million	5,000 New	5,000 $1.01 Million
Q2 2022 Nov 16, 2022	BUY	$108.81 - $179.33 $8.02 Million - $13.2 Million	73,692 New	73,692 $13 Million

Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $1.95 Million - $3.22 Million	17,965 Added 32.24%	73,692 $13 Million
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $6.67 Million - $8.8 Million	55,727 New	55,727 $8.03 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.